- Osteosarcoma in dogs: Guidelines for diagnosis, treatment and prognosis of the appendicular skeleton
- 1. Introduction
- 2. Epidemiology and Etiology
- 3. Clinical Presentation
- 4. Diagnostic procedures
- 5. Staging & Prognostic Classification
- 6. Therapy options in detail
- 7. Palliative Medicine & Pain Management
- 8. Forecasting factors
- 9. Transfer: When and where?
- FAQ about osteosarcoma in dogs
- 10. Conclusion & Outlook
- 11. Summary: Osteosarcoma in dogs – symptoms, diagnosis, treatment and prognosis
:
Osteosarcoma in dogs: Guidelines for diagnosis, treatment and prognosis of the appendicular skeleton
A comprehensive overview for veterinarians, veterinary students, and informed dog owners.
1. Introduction
The Osteosarcoma in dogs Osteosarcoma is the most common primary bone tumor in this species and presents veterinarians worldwide with significant clinical challenges. Approximately 85% of all diagnosed bone tumors in dogs are osteosarcomas. Despite decades of research, key questions regarding its pathogenesis, optimal treatment, and long-term survival remain unanswered.
This guideline is based on the current state of the literature and was developed by an international group of experts. Its aim is to support veterinary professionals in evidence-based decision-making – particularly in the management of osteosarcomas of the appendicular skeleton in dogs.
(C) From the study attached below.
2. Epidemiology and Etiology
Racial predisposition
Some dog breeds show a particularly high susceptibility to osteosarcoma. For example, Scottish Deerhounds are known to have a more than 100-fold increased risk, while Leonbergers, Great Danes, Rottweilers, and Greyhounds are also at high risk. Furthermore, Irish Wolfhounds, Saint Bernards, Labrador Retrievers, Golden Retrievers, Boxers, Dobermans, and German Shepherds are among the breeds frequently affected.
Risk factors
Size and weight play a crucial role: Large to giant dog breeds are disproportionately affected. If a dog is above average weight for its breed, the risk of osteosarcoma increases 1.65-fold. The disease most commonly occurs in animals between 7 and 9 years of age, but can also be diagnosed in young dogs as young as 18 to 24 months. Genetic mutations—especially in genes such as TP53, MYC, PTEN, RUNX2 and DLG2 – are also associated with the development of the disease. Previous fractures or infections of the bone (osteomyelitis) are considered possible additional risk factors for the later development of osteosarcoma.
3. Clinical Presentation
Symptoms
The most common clinical signs are initially intermittent, later persistent lameness, and localized pain, usually in the metaphyseal region of the long bones. Noticeable swelling over the affected bone is also a classic symptom. In approximately 3% of cases, a pathological fracture can occur, meaning a bone break without external trauma. In later stages, affected dogs often also exhibit systemic symptoms such as loss of appetite, lethargy, and weight loss.
Unusual presentations
In rare cases, osteosarcoma in dogs may present with paraneoplastic syndromes, such as hypertrophic osteopathy associated with thoracic metastases. Metastasis can also affect the lungs, other bones, skin, or lymph nodes.
4. Diagnostic procedures
Imaging procedures
X-ray diagnostics often provide typical indications of osteosarcoma: Classic features include the so-called "sunburst" pattern, the Codman triangle, and osteolytic and osteoblastic changes. Accompanying soft tissue swelling is usually also present. Joint infiltration is rare, except in the femoral head.
CT and MRI scans allow for a significantly more precise assessment of tumor extent, evaluation of fracture risk, and accurate surgical or radiation therapy planning.
Cytology (fine needle aspiration, FNA)
Fine-needle aspiration offers a rapid, minimally invasive method for cytological evaluation. Its sensitivity ranges from 70 to 97 %, and its specificity can reach up to 100 %. Since general anesthesia is not required for sample collection, this method is particularly well-suited for unstable patients. However, precise subtyping is not possible using cytology alone.
biopsy
For a reliable diagnosis, a core biopsy is recommended, for example using a Jamshidi needle. This allows for a detailed histological characterization of the tumor. Ideally, the biopsy should be taken from the center of the tumor, not the periphery. Risks include pathological fractures and the potential dissemination of tumor cells.
Laboratory diagnostics
Certain blood values, particularly elevated alkaline phosphatase (ALP), correlate with a poorer prognosis. Immunological profiles often indicate systemic inflammation, and high PTHR1 expression is also associated with shorter survival.
5. Staging & Prognostic Classification
Comprehensive staging includes an orthopedic examination with targeted palpation, supplemented by lung imaging – ideally CT or at least X-rays in three projections. Cytological examination of the regional lymph nodes provides additional information. If metastases are suspected, the use of nuclear medicine procedures such as SPECT or PET should be considered.
The modified Enneking staging system distinguishes three main stages:
Stage 1 refers to low-grade tumors without metastases.
Stage 2 includes high-grade tumors, also without metastases – this is the most common stage of the disease at diagnosis.
Stage 3 This is present when metastases are detected, for example in the lungs, lymph nodes or other bones.
Despite the lack of imaging findings, over 90% of patients already have %. micrometastatic diseases available.
6. Therapy options in detail
6.1. Surgical Treatment
The amputation Surgical removal of the affected limb remains the gold standard. In most cases, it provides immediate pain relief and is well-tolerated even in large breeds. Median survival without subsequent chemotherapy is approximately 3–4 months.
As an alternative to amputation, the so-called Limb-sparing operation This method is used, for example, in cases of tumors in the distal radius. However, it is associated with a high complication rate, particularly infections (up to 78 %), implant failure, and local recurrence. Survival time is comparable to that after amputation.
In selected cases, a Metastasectomy This involves the surgical removal of lung metastases. With a maximum of two lesions and a stable general condition, this can extend survival to up to 255 days.
6.2. Radiation therapy
The Stereotactic body radiotherapy (SBRT) This is a modern form of high-precision radiotherapy. High doses are administered in just a few sessions, resulting in significant pain reduction. However, there is a fracture risk of up to 41 %. Median survival is 233–346 days. Careful CT planning is essential.
The following is suitable as a palliative measure: Hypofractionation, in which four fractions of 6–8 Gy are administered at weekly intervals. In combination with zoledronate, the fracture risk may be reduced. This method is particularly useful in inoperable patients or those who refuse amputation.
6.3. Chemotherapy
The adjuvant chemotherapy, i.e., the use after the operation, is essential for controlling micrometastatic disease. Carboplatin It is considered the first choice due to its good tolerability. Doxorubicin It has high efficacy but is potentially cardiotoxic. Cisplatin requires intensive fluid therapy due to its nephrotoxic properties.
Treatment typically consists of 4–6 cycles at 2–3 week intervals. Combination protocols have not yet shown a significant survival benefit. In combination with amputation, survival can be extended to 8–14 months. The 1-year survival rate is approximately 40 %, and the 2-year rate is approximately 20 %.
6.4. Immunotherapy
The use of [the following] was considered successful in the past. L-MTP-PE, a liposomal peptide that can improve survival. Newer approaches include Listeria and HER2 vaccines, Checkpoint inhibitors like Gilvetmab, Adoptive T-cell therapies with IL-2, Anti-CSPG4 DNA vaccines as well as oncolytic virotherapies (e.g. with VSV) and inhalational IL-15. These therapies are considered promising, but are currently limited to specialized centers and studies.
7. Palliative Medicine & Pain Management
Effective pain therapy is essential in Osteosarcomas in dogs of central importance. This is where COX-2 inhibitors such as firocoxib or robenacoxib, supplemented by Opioids such as buprenorphine or fentanyl patches. Gabapentin and Amantadine Provides support in cases of neuropathic pain. Anti-NGF antibodies such as Bedinvetmab and Aminobisphosphonate (Zoledronate, Pamidronate) complement palliative therapy.
8. Forecasting factors
A poor prognosis is associated with an elevated ALP level, a tumor in the proximal humerus, a body weight over 40 kg, a high histological grade (grade III), a high mitotic index, and with proven lymph node or lung metastases.
In contrast, the prognosis is more favorable if the tumor has a fibroblastic subtype, is smaller than 7 cm, the body weight is less than 40 kg, or – paradoxically – a postoperative wound infection occurs after limb-sparing surgery.
9. Transfer: When and where?
Referral to a specialized clinic is always advisable when complex diagnostic procedures such as CT scans, PET scans, or biopsies are necessary, when limb-sparing surgery is being considered, or when access to innovative therapies such as SBRT or immunotherapy is required. The close collaboration between surgery and oncology also supports a referral.
FAQ about osteosarcoma in dogs
❓ 1. What is osteosarcoma in dogs and why is it so dangerous?
A Osteosarcoma in dogs is a malignant, highly aggressive tumor that originates from the bone-forming cells (osteoblasts). It is the most common form of primary bone tumor in dogs and makes about 85 % of all bone tumors Osteosarcoma most commonly affects the long bones of the limbs – that is, the so-called skeletal system. appendicular skeleton – including in particular the distal radius, the proximal humerus, the distal femur and the proximal tibia.
The danger of osteosarcoma lies in its high local aggressiveness and the early metastasis. Already at the time of diagnosis, over 90 of the affected dogs had % microscopic metastases, These metastases are usually located in the lungs, but can also be found in other bones or lymph nodes. At this stage, these metastases are usually not yet visible on imaging, which underscores the importance of early detection. systemic therapy additionally emphasizes.
Another risk factor lies in the local destructive power of the tumor. It not only causes pain, but weakens the affected bone so severely that it leads to pathological fractures This can occur – that is, bone fractures that occur without external force.
Overall, osteosarcoma in dogs is considered a very serious oncological emergency, which requires rapid action, thorough diagnostics and coordinated multimodal treatment.
❓ 2. What treatment options are available for osteosarcoma and how do they affect life expectancy?
The treatment of the Osteosarcoma in dogs is complex and requires a combination of different treatment methods – the so-called multimodal therapy. The aim is to both the to control the primary tumor locally as well as the to contain systemic metastasis. There are essentially four proven treatment approaches:
Surgical amputation:
Complete removal of the affected limb is currently the only option. most effective method, to eliminate tumor pain and the risk of fracture. Many owners are afraid of amputation, but reality shows that dogs – even large breeds – cope very well with three legs. Without additional therapy, the median survival time is approximately 3 to 5 months..
Adjuvant chemotherapy:
Since almost all osteosarcoma patients already have metastases in their body, chemotherapy is highly recommended. The use of medications such as Carboplatin or Doxorubicin After amputation, the average survival time increases to 8 to 14 months, although some dogs also more than two years survive.
Radiation therapy (SBRT):
For dogs where amputation is not possible or is refused, stereotactic radiotherapy presents an alternative. It offers excellent pain reduction and, in combination with chemotherapy, can prolong survival similarly to amputation. However, the risk of fracture remains.
Immunotherapy (experimental):
New approaches with Checkpoint inhibitors, Vaccines or adoptive T-cell therapies They offer promising future prospects, but are currently only available in studies or specialized centers.
Ultimately, life expectancy depends heavily on the chosen therapy, the dog's overall health, the tumor location, and the presence of metastases. Dogs receiving a combination of local and systemic therapy now have a longer life expectancy. realistic chances for a good year with a high quality of life.
❓ 3. How can I recognize osteosarcoma in dogs early? Are there any warning signs?
A Osteosarcoma in dogs It often develops gradually, but shows some typical warning signs that can indicate the disease – especially in large dog breeds in middle to old age. The most common early symptoms are:
Lameness, which either occurs suddenly or increases over days/weeks
One localized swelling on a bone of the limb
Pain when walking, climbing stairs or even petting
Protective posture or refusal of movement
In some cases: sudden bone fracture without trauma (pathological fracture)
These symptoms can initially point to harmless causes such as sprains, arthritis, or bruises – which is precisely what makes early detection difficult. Many dogs are mistakenly given painkillers or anti-inflammatories in the initial phase, which improves the symptoms in the short term but delays the diagnosis.
A particularly important warning sign is when a dog Initially lame, then seemingly recovers, and after a short time lames again – usually more severely than before. This suggests that the tumor is progressing, while painkillers are only masking the symptoms.
If a veterinarian or owner recognizes these signs – especially in a predisposed breed – they should An X-ray should be taken immediately.. This is the only way to detect osteosarcoma with a high degree of probability in its early stages. Early diagnosis significantly improves the prognosis.
❓ 4. What is a dog's quality of life after an amputation? Can large dogs also live with three legs?
Many dog owners understandably have serious concerns about amputation – especially with large breeds. However, experience repeatedly shows that most dogs – even large and heavy ones – They get along perfectly well with three legs..
Immediately after the operation, they naturally need a period of rehabilitation and support. But already a few days after the amputation Many dogs show significant improvements in their general behavior. The biggest advantage is that the Tumor pain disappears immediately, which is reflected in a visibly improved sense of well-being and increased activity.
Studies and clinical experience prove that amputee dogs:
No problems again. walking, running and playing
climb stairs or be able to jump into the car
A comparable Joy of life and mobility as shown before
No psychological damage suffer (which often occur in humans)
Of course, individual fitness, weight, and any pre-existing conditions play a role. But older or overweight dogs almost always benefit from amputation – especially if the tumor is causing severe pain.
For many owners, the moment when their dog after the amputation, walking happily again or wagging its tail, This proves they made the right decision. Fear is understandable, but Quality of life means freedom from pain – not the number of legs..
❓ 5. What does the treatment for osteosarcoma in dogs cost, and is the investment worthwhile?
The cost of treating a Osteosarcoma in dogs Treatment outcomes can vary significantly depending on the type of therapy, region, and veterinary clinic. Here's a general overview:
Treatment method
Cost framework (estimated)
X-ray + biopsy
€300–700
CT or MRI
€500–1,500
amputation
€1,000–2,500
Chemotherapy (4–6 cycles)
€1,500–3,000
Radiation therapy (SBRT)
€2,500–€5,000
Palliative medicine monthly
€100–300
A complete, curative treatment with amputation and adjuvant chemotherapy is usually possible in 3,000 to 6,000 euros. If radiation therapy or immunotherapy is also used, the total cost can be significantly higher.
Now to the crucial question: Is this investment worthwhile? The answer depends on several factors:
Quality of life: The therapy cannot cure, but months of life in good condition give.
Life expectancy gain: Without treatment, 3–5 months; with therapy, up to 14 months or longer.
Emotional component: For many pet owners, every pain-free week with their animal is priceless.
Additionally, there is the possibility to, Pet health insurance or surgical insurance to complete – some of them also cover oncological treatments.
If you react early, your dog will receive a real chance for life with quality of life – and that is the value that many owners consider higher than any sum in euros.
10. Conclusion & Outlook
Osteosarcoma in dogs is one of the most aggressive neoplastic diseases of the skeleton. Thanks to modern diagnostics, multimodal treatment concepts, and interdisciplinary collaboration, the survival time of affected dogs can be significantly extended – often with a good quality of life.
The key to successful treatment lies in the early diagnosis, a sound staging and a individual therapy planning – ideally in close coordination with specialized veterinary clinics.
11. Summary: Osteosarcoma in dogs – symptoms, diagnosis, treatment and prognosis
The Osteosarcoma in dogs is the most common form of bone cancer in dogs and primarily affects the appendicular skeleton, meaning the limbs. Approximately 85% of all primary bone tumors in dogs fall into this category. Osteosarcoma in dogs is considered particularly aggressive because it grows destructively in the local area and metastasizes early to other organs – especially the lungs.
The causes of a Osteosarcoma in dogs The risks are diverse. Particularly large dog breeds such as Rottweilers, Great Danes, or Irish Wolfhounds show a significantly increased risk. Additionally, genetic factors, high body weight, early neutering, and possibly previous bone injuries or fractures also play a role.
Dogs with Osteosarcoma Initially, the symptoms are nonspecific. Typically, a sudden or gradual lameness Symptoms may initially appear treatable with painkillers. Swelling over the affected bone and increasing sensitivity to pain are classic warning signs. It is particularly dangerous if a Osteosarcoma in dogs Pathological fractures are often only discovered after a bone breaks – they usually indicate a far advanced stage of the disease.
To diagnose a Osteosarcoma in dogs The primary diagnostic tool is an X-ray. Typical features – such as osteolysis, a sunburst pattern, or a Codman triangle – often allow for a preliminary diagnosis. Imaging is supplemented by fine-needle aspiration (FNA) or biopsy for histological confirmation.
An important step in the assessment of the Osteosarcoma in dogs Staging, or determining the tumor stage, is the next step. CT scans, chest X-rays, and possibly scintigraphy are used to determine whether metastases are present. Even if no metastases are detected, in over 90% of cases of % Micrometastases to assume that systemic treatment is necessary.
The therapy of Osteosarcoma in dogs This usually requires a multimodal approach. Amputation of the affected limb It is considered a standard procedure for local tumor control. It offers immediate pain relief and reduces the risk of fracture. Contrary to many fears, dogs, even large breeds, generally cope very well with three legs.
Alternatively, Limb-sparing operations These procedures are performed to preserve the limb, especially in cases of tumors in the distal radius. However, they carry an increased risk of infection and implant failure. In inoperable cases, stereotactic body radiation therapy (SBRT) is an option – a modern, precise radiation method that also helps control pain.
Another important component of the treatment at Osteosarcoma in dogs Chemotherapy is the primary treatment. Since the risk of systemic metastases is high, adjuvant chemotherapy with carboplatin or doxorubicin has been proven to improve survival. Concomitant systemic therapy is also standard practice in limb-sparing or SBRT.
In advanced cases, or when curative therapy is not possible, palliative measures are used. palliative care for osteosarcoma in dogs This includes pain medication (e.g., NSAIDs, opioids), bisphosphonates to inhibit bone destruction, and possibly radiation therapy to relieve pain.
The Prognosis for osteosarcoma in dogs It depends on many factors. Without treatment, survival time is usually less than 5 months. With amputation and chemotherapy, it can be increased to 10 to 14 months. Some dogs even survive 2 years or longer – especially with favorable tumor location, low ALP levels, and no metastases.
New therapies such as immunotherapies are increasingly being used. Studies on PD-1 inhibitors, vaccines, or oncolytic viruses are showing initial success, but are currently mostly limited to specialized veterinary clinics. Looking ahead, it appears that... Osteosarcoma in dogs Personalized therapies allow for even more targeted treatment.
Special attention should be paid to pain management. Osteosarcoma in dogs It causes intense pain, which can be both somatic and neuropathic. A combination of COX-2 inhibitors, gabapentin, amantadine, and, if necessary, anti-NGF antibodies (e.g., bedinvetmab) is now standard practice.
Overall, this is Osteosarcoma in dogs A very serious illness – but not hopeless. Early diagnosis, targeted therapy, and good palliative care can give many dogs more time and improve their quality of life. The emotional strain on owners is understandable, but choosing effective treatment – including amputation – is often the best option for the animal.
Conclusion: The Osteosarcoma in dogs It is a challenge, but treatable with modern veterinary medicine. With the right combination of surgery, chemotherapy, and pain management, many animals can live pain-free and happy lives for a long time.
The study underlying this article is: study Download here
Further links: